BADERC-David Nathan

David Nathan, M.D.

Clinical Research in Type 1 and Type 2 Diabetes

Dr. David M. Nathan is an internationally recognized expert on diabetes and its complications. He is currently Director of the General Clinical Research Center and of the Diabetes Clinical Research Center at Massachusetts General Hospital. His major research focus is the study and development of new treatments of diabetes mellitus and the long-term consequences of such therapy. He has helped develop and investigated external and implantable pump therapy, and islet and whole organ transplantation for Type 1 diabetes, and new pharmacologic agents and hormones (e.g., GLP1) in the treatment of Type 2 diabetes. Dr. Nathan is an active participant in epidemiologic studies of diabetes and cardiovascular disease through the Framingham Heart Study, Nurses Health Study, and Baltimore Longitudinal Study of Aging. He was one of the architects of the Diabetes Control and Complications Trial, serving as Editor for DCCT publicatons. Dr. Nathan currently co-chairs the national Epidemiology of Diabetes Interventions and Complications Study, which is examining the long-term impact of diabetes and associated risk factors on micro- and macrovascular disease in Type 1 diabetes. He also is the Chairman of the Diabetes Prevention Program and Diabetes Prevention Program Outcome Study, a NIH-sponsored multicenter trials that demonstrated the ability to prevent Type 2 diabetes and are continuing to examine the long-term outcomes of prevention of Type 2 diabetes. Dr. Nathan is also the Principal Investigator at the MGH of the LookAHEAD study and the TODAY study which are examining the long term impact of lifestyle interventions in Type 2 diabetes and the optimal therapy for Type 2 diabetes in adolescents and youth, respectively.

References:

1. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D’Agostino RB, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-28.

2. Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM for the EDIC Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381-9.

3. Meigs JB, Nathan DM, Ordovas JM, Schaefer EJ, Cupples LA, Singer DE, Wilson PWF. Apoliporprotein E isoform polymorphisms are not associated with insulin resistance. Diabetes Care 2000;23: 669-74.

4. Manson JE, Ajani UA, Liu S, Nathan DM, Hennekens CH. A prospective study of cigarette smoking and incidence of diabetes mellitus among U.S. male physicians. Am J Med 2000; 109:538-42.

5. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Int Med 2001; 161:1717-23.

6. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. Diabetes Care 2001; 24:1403-1410.

7. Delahanty LM, Sonnenberg LM, Hayden D, Nathan DM. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled clinical trial. JADA 2001;101:1012-23.

8. Meigs JB, Haffner SM, Nathan DM, D’Agostino RB, Wilson PWF. Sample exchange to compare insulin measurements between the San Antonio Heart Study and Framingham Offspring Study. J Clin Epidemiol 2001; 54:1031-36.

9. Lopes de Faria JM, Katsumi O, Cagliero E, Nathan DM, Hirose T. Neurovisual abnormalities precede retinopathy in patients with long-term Type 1 diabetes. Graefe’s Arch Clin Exp Ophthalmol 2001; 239: 643-48.

10. Knowler WC, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E, Nathan DM for the DPP Research Group. Reduction in incidence of Type 2 diabetes with life-style intervention or metformin. N Engl J Med 2002; 346:393-403.

11. Meigs JB, D’Agostino RB, Nathan DM, Rifal N, Wilson PWF. Longitudinal association of glycemia and microalbuminuria. Diabetes Care 2002; 25:977-83.

12. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med 2002;112: 603-609.

13. Genuth S, Lachin J, Cleary, P, Nathan DM for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.

14. Nathan DM. The impact of clinical trials on the treatment of diabetes mellitus. JCEM 2002;87:1929-1935.

15. Barr GR, Nathan DM, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Int Med 2002;137:263-72.

16. Cagliero E, Apruzzese W, Perlmutter GS, Nathan DM. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. Am J Med 2002; 112: 487-90.

17. Meigs JB, Larson MG, D’Agostino RB, Levy D, Clouse ME, Nathan DM, Wilson PWF, O’Donnell CJ. Coronary artery calcification in type 2 diabetes and insulin resistance. Diabetes Care 2002;25:1313-19.

18. Delahanty LM, Hayden D, Ammerman A, Nathan DM. Medical nutrition therapy for hypercholesterolemia positively affects patient satisfaction and quality of life outcomes. Ann Behav Med 2002;24:269-78.

19. Delahanty LM, Meigs JB, Hayden, Nathan DM. Psychological and behavioral correlates of baseline BMI in the Diabetes Prevention Program (DPP). Diabetes care 2002; 25: 1992-1998.

20. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002; 347:1342-1349.

21. Meigs JB, Nathan DM, D’Agostino RB, Wilson PWF. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25:1845-50.

22. Goldhaber-Fiebert J, Goldhaber-Fiebert S, Tristan ML, Nathan DM. Randomized controlled community-based nutrition and exercise intervention imoproves glycemia and cardiovascular risk factors in type 2 diabetes in rural Costa Rica. Diabetes Care 2003; 26: 24-29.

23. Meigs JB, Cagliero E, Dubey A, Murphy-Sheehy P, Gildesgame C, Chueh H, Barry MJ, Singer DE, Nathan DM. A controlled trial of web-based diabetes disease management: the MGH Diabetes Primary Care Improvement Project. Diabetes Care 2003;26:750-57.






			David Nathan, M.D. Clinical Research in Type 1 and Type 2 Diabetes Dr. David M. Nathan is an internationally recognized expert on diabetes and its complications. He is currently Director of the General Clinical Research Center and of the Diabetes Clinical Research Center at Massachusetts General Hospital. His major research focus is the study and development of new treatments of diabetes mellitus and the long-term consequences of such therapy. He has helped develop and investigated external and implantable pump therapy, and islet and whole organ transplantation for Type 1 diabetes, and new pharmacologic agents and hormones (e.g., GLP1) in the treatment of Type 2 diabetes. Dr. Nathan is an active participant in epidemiologic studies of diabetes and cardiovascular disease through the Framingham Heart Study, Nurses Health Study, and Baltimore Longitudinal Study of Aging. He was one of the architects of the Diabetes Control and Complications Trial, serving as Editor for DCCT publicatons. Dr. Nathan currently co-chairs the national Epidemiology of Diabetes Interventions and Complications Study, which is examining the long-term impact of diabetes and associated risk factors on micro- and macrovascular disease in Type 1 diabetes. He also is the Chairman of the Diabetes Prevention Program and Diabetes Prevention Program Outcome Study, a NIH-sponsored multicenter trials that demonstrated the ability to prevent Type 2 diabetes and are continuing to examine the long-term outcomes of prevention of Type 2 diabetes. Dr. Nathan is also the Principal Investigator at the MGH of the LookAHEAD study and the TODAY study which are examining the long term impact of lifestyle interventions in Type 2 diabetes and the optimal therapy for Type 2 diabetes in adolescents and youth, respectively. References: 1. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D’Agostino RB, Wilson PWF. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-28. 2. Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM for the EDIC Research Group. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381-9. 3. Meigs JB, Nathan DM, Ordovas JM, Schaefer EJ, Cupples LA, Singer DE, Wilson PWF. Apoliporprotein E isoform polymorphisms are not associated with insulin resistance. Diabetes Care 2000;23: 669-74. 4. Manson JE, Ajani UA, Liu S, Nathan DM, Hennekens CH. A prospective study of cigarette smoking and incidence of diabetes mellitus among U.S. male physicians. Am J Med 2000; 109:538-42. 5. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Int Med 2001; 161:1717-23. 6. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. Diabetes Care 2001; 24:1403-1410. 7. Delahanty LM, Sonnenberg LM, Hayden D, Nathan DM. Clinical and cost outcomes of medical nutrition therapy for hypercholesterolemia: a controlled clinical trial. JADA 2001;101:1012-23. 8. Meigs JB, Haffner SM, Nathan DM, D’Agostino RB, Wilson PWF. Sample exchange to compare insulin measurements between the San Antonio Heart Study and Framingham Offspring Study. J Clin Epidemiol 2001; 54:1031-36. 9. Lopes de Faria JM, Katsumi O, Cagliero E, Nathan DM, Hirose T. Neurovisual abnormalities precede retinopathy in patients with long-term Type 1 diabetes. Graefe’s Arch Clin Exp Ophthalmol 2001; 239: 643-48. 10. Knowler WC, Barrett-Connor E, Fowler S, Hamman R, Lachin J, Walker E, Nathan DM for the DPP Research Group. Reduction in incidence of Type 2 diabetes with life-style intervention or metformin. N Engl J Med 2002; 346:393-403. 11. Meigs JB, D’Agostino RB, Nathan DM, Rifal N, Wilson PWF. Longitudinal association of glycemia and microalbuminuria. Diabetes Care 2002; 25:977-83. 12. Grant RW, Cagliero E, Murphy-Sheehy P, Singer DE, Nathan DM, Meigs JB. Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med 2002;112: 603-609. 13. Genuth S, Lachin J, Cleary, P, Nathan DM for the DCCT/EDIC Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569. 14. Nathan DM. The impact of clinical trials on the treatment of diabetes mellitus. JCEM 2002;87:1929-1935. 15. Barr GR, Nathan DM, Meigs JB, Singer DE. Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Int Med 2002;137:263-72. 16. Cagliero E, Apruzzese W, Perlmutter GS, Nathan DM. Musculoskeletal disorders of the hand and shoulder in patients with diabetes mellitus. Am J Med 2002; 112: 487-90. 17. Meigs JB, Larson MG, D’Agostino RB, Levy D, Clouse ME, Nathan DM, Wilson PWF, O’Donnell CJ. Coronary artery calcification in type 2 diabetes and insulin resistance. Diabetes Care 2002;25:1313-19. 18. Delahanty LM, Hayden D, Ammerman A, Nathan DM. Medical nutrition therapy for hypercholesterolemia positively affects patient satisfaction and quality of life outcomes. Ann Behav Med 2002;24:269-78. 19. Delahanty LM, Meigs JB, Hayden, Nathan DM. Psychological and behavioral correlates of baseline BMI in the Diabetes Prevention Program (DPP). Diabetes care 2002; 25: 1992-1998. 20. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002; 347:1342-1349. 21. Meigs JB, Nathan DM, D’Agostino RB, Wilson PWF. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25:1845-50. 22. Goldhaber-Fiebert J, Goldhaber-Fiebert S, Tristan ML, Nathan DM. Randomized controlled community-based nutrition and exercise intervention imoproves glycemia and cardiovascular risk factors in type 2 diabetes in rural Costa Rica. Diabetes Care 2003; 26: 24-29. 23. Meigs JB, Cagliero E, Dubey A, Murphy-Sheehy P, Gildesgame C, Chueh H, Barry MJ, Singer DE, Nathan DM. A controlled trial of web-based diabetes disease management: the MGH Diabetes Primary Care Improvement Project. Diabetes Care 2003;26:750-57.